Related Research Articles
The Princess of Asturias Awards, formerly the Prince of Asturias Awards from 1981 to 2014, are a series of annual prizes awarded in Spain by the Princess of Asturias Foundation to individuals, entities or organizations from around the world who make notable achievements in the sciences, humanities, and public affairs.
Rosalyn Sussman Yalow was an American medical physicist, and a co-winner of the 1977 Nobel Prize in Physiology or Medicine for development of the radioimmunoassay technique. She was the second woman, and the first American-born woman, to be awarded the Nobel Prize in Physiology or Medicine.
Ronald Mark Evans is an American Biologist, Professor and Head of the Salk’s Gene Expression Laboratory, and the March of Dimes Chair in Molecular and Developmental Biology at the Salk Institute for Biological Studies in La Jolla, California and a Howard Hughes Medical Institute Investigator. Dr. Ronald M. Evans is known for his original discoveries of nuclear hormone receptors (NR), a special class of transcriptional factor, and the elucidation of their universal mechanism of action, a process that governs how lipophilic hormones and drugs regulate virtually every developmental and metabolic pathway in animals and humans. Nowadays, NRs are among the most widely investigated group of pharmaceutical targets in the world, already yielding benefits in drug discovery for cancer, muscular dystrophies, osteoporosis, type II diabetes, obesity, and cardiovascular diseases. His current research focuses on the function of nuclear hormone signaling and their function in metabolism and cancer.
Incretins are a group of metabolic hormones that stimulate a decrease in blood glucose levels. Incretins are released after eating and augment the secretion of insulin released from pancreatic beta cells of the islets of Langerhans by a blood-glucose–dependent mechanism.
The Canada Gairdner International Award is given annually by the Gairdner Foundation at a special dinner to five individuals for outstanding discoveries or contributions to medical science. Receipt of the Gairdner is traditionally considered a precursor to winning the Nobel Prize in Medicine; as of 2020, 98 Nobel Prizes have been awarded to prior Gairdner recipients.
Robert Samuel Langer Jr. FREng is an American biotechnologist, businessman, chemical engineer, chemist, and inventor. He is one of the nine Institute Professors at the Massachusetts Institute of Technology.
Enteroglucagon is a peptide hormone derived from preproglucagon. It is a gastrointestinal hormone, secreted from mucosal cells primarily of the colon and terminal ileum. It consists of 37 amino acids. Enteroglucagon is released when fats and glucose are present in the small intestine; which decrease the motility to allow sufficient time for these nutrients to be absorbed.
Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon peptide. It is produced and secreted by intestinal enteroendocrine L-cells and certain neurons within the nucleus of the solitary tract in the brainstem upon food consumption. The initial product GLP-1 (1–37) is susceptible to amidation and proteolytic cleavage, which gives rise to the two truncated and equipotent biologically active forms, GLP-1 (7–36) amide and GLP-1 (7–37). Active GLP-1 protein secondary structure includes two α-helices from amino acid position 13–20 and 24–35 separated by a linker region.
Jeffrey M. Friedman is a molecular geneticist at New York City's Rockefeller University and an Investigator of the Howard Hughes Medical Institute. His discovery of the hormone leptin and its role in regulating body weight has had a major role in the area of human obesity. Friedman is a physician scientist studying the genetic mechanisms that regulate body weight. His research on various aspects of obesity received national attention in late 1994, when it was announced that he and his colleagues had isolated the mouse ob gene and its human homologue. They subsequently found that injections of the encoded protein, leptin, decreases body weight of mice by reducing food intake and increasing energy expenditure. Current research is aimed at understanding the genetic basis of obesity in human and the mechanisms by which leptin transmits its weight-reducing signal.
The glucagon-like peptide-1 receptor (GLP1R) is a G protein-coupled receptor (GPCR) found on beta cells of the pancreas and on neurons of the brain. It is involved in the control of blood sugar level by enhancing insulin secretion. In humans it is synthesised by the gene GLP1R, which is present on chromosome 6. It is a member of the glucagon receptor family of GPCRs. GLP1R is composed of two domains, one extracellular (ECD) that binds the C-terminal helix of GLP-1, and one transmembrane (TMD) domain that binds the N-terminal region of GLP-1. In the TMD domain there is a fulcrum of polar residues that regulates the biased signaling of the receptor while the transmembrane helical boundaries and extracellular surface are a trigger for biased agonism.
The G protein-coupled bile acid receptor 1 (GPBAR1) also known as G-protein coupled receptor 19 (GPCR19), membrane-type receptor for bile acids (M-BAR) or Takeda G protein-coupled receptor 5 (TGR5) is a protein that in humans is encoded by the GPBAR1 gene. Activated by bile acids, these receptors play a crucial role in metabolic regulation, including insulin secretion and energy balance, and are found in the gastrointestinal tract as well as other tissues throughout the body.
Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 analogs, GLP-1DAs, or incretin mimetics, are a class of anorectic drugs that reduce blood sugar and energy intake by activating the GLP-1 receptor. They mimic the actions of the endogenous incretin hormone GLP-1, which is released by the gut after eating.
Douglas L. Coleman was a scientist and professor emeritus at the Jackson Laboratory, in Bar Harbor, Maine. His work predicted that there exists a hormone that can cause mice to feel full, and that a mutation in the gene encoding this hormone can lead to obesity. The gene and corresponding hormone were discovered about 20 years later by Jeffrey M. Friedman, Rudolph Leibel, and their research teams at Rockefeller University, which Friedman named leptin.
Daniel Joshua Drucker is a Canadian endocrinologist. A Fellow of the Royal Society, he is a professor of medicine at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto. He is known for his research into intestinal hormones and their use in the treatment of diabetes, obesity, and other metabolic diseases, as well as intestinal failure.
Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain. It can be administered by subcutaneous injection or taken orally. It is sold by Novo Nordisk under the brand names Ozempic and Rybelsus for diabetes, and under the brand name Wegovy for weight management and weight loss.
The Banting Medal, officially the Banting Medal for Scientific Achievement, is an annual award conferred by the American Diabetes Association (ADA), which is the highest award of ADA. Inaugurated in 1941, the prize is given in memory of Sir Frederick Banting, a key discoverer of insulin and its therapeutic use.
Joel Habener is a Professor of Medicine at Harvard Medical School and an Associate Physician at the Massachusetts General Hospital.
Svetlana Mojsov is a Macedonian American, ex-Yugoslavian-born chemist who is a research associate professor at Rockefeller University. Her research considers peptide synthesis. She discovered the glucagon-like peptide-1 and uncovered its role in glucose metabolism and the secretion of insulin. Her breakthroughs were transformed by Novo Nordisk into therapeutic agents against diabetes and obesity.
Lotte Bjerre Knudsen is a Danish scientist and university professor. She led the development of liraglutide and oversaw the development of semaglutide, two notable drugs approved for indications in the treatment of diabetes and obesity.
Arne Vernon Astrup is a Danish nutritionist, chief physician, researcher, author and professor. He is known as a researcher, communicator and author and has published more than 900 scientific articles. In 2018 he was internationally recognised as one of the world's most cited researchers. Arne Astrup has contributed to the identification of GLP-1 as a satiety hormone, which has played a key role in the development of GLP-1 drugs for the treatment of obesity, which has contributed to the success of Novo Nordisk A/S and their drug Wegovy.
References
- ↑ Singh G, Krauthamer M, Bjalme-Evans M (January 2022). "Wegovy (semaglutide): a new weight loss drug for chronic weight management". Journal of Investigative Medicine. 70 (1): 5–13. doi:10.1136/jim-2021-001952. PMC 8717485 . PMID 34706925.
- ↑ Astrup, Arne (2024). "Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions". European Journal of Clinical Nutrition. 78 (7): 551–556. doi:10.1038/s41430-024-01460-6. ISSN 0954-3007. PMC 11230893 . PMID 38890501.
- ↑ Prize Recipients | Warren Alpert Foundation Prize
- ↑ "2021 Canada Gairdner Awards Recognize World-Renowned Scientists For Transformative Contributions To Research Impacting Human Health". 7 April 2021. Retrieved 13 December 2021.
- ↑ "Exceptional Leaders in Diabetes Research, Prevention and Treatment to be Recognized at ADA's 81st Scientific Sessions" (PDF; 269 kB). diabetes.org. American Diabetes Association. 2021-03-08.
- ↑ "Daniel J. Drucker, Jeffrey M. Friedman, Joel F. Habener, Jens Juul Holst, and Svetlana Mojsov, Princess of Asturias Award for Technical and Scientific Research 2024". Princess of Asturias Foundation. 5 June 2024.
- ↑ Tang Prize 2024
- ↑ BBVA Foundation Frontiers of Knowledge Award 2024
| International | |
|---|---|
| National | |
| Academics | |
| Other | |
 | This biographical article related to medicine is a stub. You can help Wikipedia by expanding it. |